Glycostem's NK Cell Product oNKord® received Orphan drug designation for AML

18 November 2014, EMA/COMP/641491/2014
During their plenary meeting on 11-13 November 2014 the Committee for Orphan Medicinal Products (COMP) has adopted at the first discussion a positive opinion recommending Glycostem's NK Cell Product* for designation as orphan medicinal product to the European Commission (EC).

*) Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells for treatment of acute myeloid leukaemia